← Browse by Condition
Medical Condition
extensive stage small cell lung cancer es sclc
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1, Phase 2
NCT05787587 Phase 1
Recruiting
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Enrollment
216 pts
Location
United States
Sponsor
IDEAYA Biosciences
NCT06758700 Phase 2
Recruiting
Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
Enrollment
15 pts
Location
China
Sponsor
Shanghai Pulmonary Hospital, S...